[Temporary Announcement] Hongzhong Pharmaceutical: Announcement of Appointment of Financial Director

Announcement number: 2026-003

Securities code: 833746 Securities abbreviation: Hongzhong Pharmaceutical Sponsored securities firm: Cathay Haitong

Announcement on the Appointment of the Financial Director of Hubei Hongzhong Pharmaceutical Co., Ltd.

The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.

1. Basic situation of appointment and removal

(1) Basic information on appointment and removal

In accordance with the relevant provisions of the Company Law and the Articles of Association, the ninth meeting of the company's sixth board of directors reviewed and passed the "Proposal on the Appointment of Mr. Shu Zhiwu as the Company's Financial Director" on January 14, 2026.

Mr. Shu Zhiwu was appointed as the company’s financial controller. His term of office will end on the expiration of the fourth term of the board of directors, effective from January 14, 2026. The above-mentioned appointees hold 339,629 shares of the company, accounting for 0.87% of the company’s share capital, and are not targets of joint punishment for breach of trust.

(2) Reasons for appointment

Mr. Liu Xiang, the former financial director, applied to resign from his position as financial director due to personal reasons. In order to ensure the company's sustainable and stable operations, in accordance with the relevant provisions of the "Company Law of the People's Republic of China", the "Articles of Association" and relevant administrative regulations, Mr. Shu Zhiwu (Secretary of the Board of Directors) was appointed as the company's financial director after review.

2. The impact of appointment on the company

The qualifications of candidates for the company's new directors, supervisors, and senior managers shall comply with laws, regulations, departmental regulations, business rules, and company articles of association.

In this appointment, there is no situation where the company's directors or senior managers concurrently serve as the company's supervisors; there is no situation where the company's supervisors are the spouses or immediate family members of the company's directors or senior managers.

Impact on the company’s production and operations:

This appointment will be conducive to improving the company's governance structure, conducive to the stability and implementation of the company's financial policies, and will have a positive impact on the company's future operations and development.

3. Documents for reference

"Resolution of the Fourth Meeting of the Fourth Board of Directors of Hubei Hongzhong Pharmaceutical Co., Ltd."

Hubei Hongzhong Pharmaceutical Co., Ltd. Board of Directors/Board of Supervisors January 14, 2026